FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
Experts urge early detection & better access to care
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Final decision from the European Commission is anticipated within the coming months
The trademark rights for these brands will be transferred to Lupin by March next year.
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Subscribe To Our Newsletter & Stay Updated